Login

  • Lost your password?
  • Or, login with:
  • New User? Sign up here!

Retrieve Password


Substance.com

Get involved in the conversation.

Substance.com Substance.com

Graphic: This Is How Sovaldi Price-Gouging Is Costing Lives


Gilead Sciences is making big bucks from a drug that is priced too high for many hep C sufferers to access.

3 Substance
Score


This week the pharmaceutical manufacturer Gilead Sciences released its second quarter earnings, showing sales for the new hepatitis C drug Sovaldi reaching $3.5 billion—a 52% increase in just three months. Small-scale trials suggest that when taken in combination with Olysio, another new antiviral, Sovaldi can effectively cure 90% of hep C cases. But the drug is prohibitively priced—at $1,000 per pill in the US—leading to rationing and restrictions by insurance companies.

Read the full Substance.com report by Bob Lederer here.

HepCInfograph Final